Between 2025 and 2030, biopharma faces its steepest loss-of-exclusivity wave on record.
Among the top 15 companies alone, roughly $275B in revenue is exposed. Keytruda’s core US patent lapses in 2028. Eliquis and Opdivo face generics the same year. Stelara already lost protection and its revenue fell from $21.2B to $9B in two years.
These aren’t mid-tier assets. They’re the products that built entire P&Ls.
Every strategy deck addressing this leans on the same levers: accelerate the pipeline, defend with reformulations, do more M&A, cut costs.
All necessary. All incomplete.
None of it works without the right leadership to execute it and that’s the variable most boards haven’t priced in.
A patent cliff doesn’t just erode revenue, it obsoletes the leadership profiles that built the blockbuster in the first place.
The commercial leader who scaled a $10B franchise isn’t automatically who can launch five smaller assets into fragmented indications.
The R&D team built for life-cycle extension isn’t the team that originates the next blockbuster on a compressed timeline, under investor scrutiny.
That transition has to happen years before exclusivity lapses on a fixed clock the board doesn’t control.
And the data on board readiness isn’t reassuring:
→ Korn Ferry: boards were unprepared for 1 in 4 CEO successions
→ Only 30% of pharma companies have a board-approved succession plan covering all C-suite roles
→ 61% of US boards lack a documented succession strategy at all
Not because directors don’t know it matters. Because it’s uncomfortable, it gets deferred, and there’s rarely a forcing function that makes the deferral visible.
The patent cliff is that forcing function. It puts a date on the calendar.
Boards handling this well aren’t waiting for a vacancy. They’re mapping leadership readiness against the LOE calendar asking not who reports to whom today but who needs to be running R&D, manufacturing, and commercial in 2027 for 2028’s losses to be survivable, and is that person already here.
They’re building bench strength years in advance – CMC and senior regulatory searches can already run 6-9 months in this market. And they’re protecting confidentiality through the process, because losing a finalist to a late counter-offer costs months against a date that isn’t moving.
Succession tied to a $275B revenue event isn’t continuity planning. It’s risk management, on the same footing as the R&D and commercial strategy boards already scrutinize closely.
A brilliant pipeline strategy without the leadership to run it is just a plan.
Does your board treat succession planning as risk management or as an HR agenda item? Curious how this varies by company.
For a discussion on your organization’s leadership readiness, please feel free to connect directly.
